Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H28N2O2.ClH |
| Molecular Weight | 460.995 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C4=CC=CC=C4
InChI
InChIKey=VMIZTXDGZPTKIK-UHFFFAOYSA-N
InChI=1S/C28H28N2O2.ClH/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23;/h1-15H,16-21H2,(H,31,32);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C28H28N2O2 |
| Molecular Weight | 424.5341 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. Motofen(R) is a combination of atropine, an anticholinergic drug, and difenoxin, an antidiarrheal drug. It has been used in many countries for many years as a second line opioid-agonist antidiarrheal, which exists an intermediate between loperamide and paragoric. Diarrhea which is a result of cyclic or diarrhea predominant Inflammatory Bowel Syndrome may not be treated effectively with difenoxin, diphenoxylate, or loperamide. As such, diarrhea and cramping which does not respond to non-centrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine. In patients with acute ulcerative colitis, as induction of toxic megacolon is possible, and thus use of Motofen(R) is cautioned. Motofen(R) has been assigned pregnancy category C by the FDA, and is to be used only when the potential benefits outweigh the potential risk to the fetus. The safety of use during lactation is unknown and thus not recommended. Each five-sided dye free MOTOFEN® tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin
hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine). Difenoxin acts as an antidiarrheal by activating peripheral opioid receptors in the small intestine and thereby inhibiting peristalsis. However, research has suggested that non-opioid receptor pathways exist. This would explain the potent antidiarrheal effects of difenoxin despite only limited opioid action.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
|||
Target ID: GO:0030432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8583364 |
10.4 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | MOTOFEN Approved UseMOTOFEN® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute
exacerbations of chronic functional diarrhea. Launch Date1978 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Nausea... Other AEs: Nausea (1 patient) Sources: |
2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Vomiting, Dry mouth... Other AEs: Vomiting (1 patient) Sources: Dry mouth (1 patient) |
2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Epigastric distress... Other AEs: Epigastric distress (1 patient) Sources: |
2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Constipation, Dizziness... Other AEs: Constipation (1 patient) Sources: Dizziness (1 patient) |
2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Light headedness... Other AEs: Light headedness (1 patient) Sources: |
2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Drowsiness, Headache... Other AEs: Drowsiness (1 patient) Sources: Headache (1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Dry mouth | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Vomiting | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Epigastric distress | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Constipation | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Dizziness | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Light headedness | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Drowsiness | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
| Headache | 1 patient | 2 mg multiple, oral Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Sample Use Guides
Each five-sided dye free MOTOFEN® tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin
hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine). The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1
tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8
tablets. In the treatment of diarrhea, if clinical improvement is not observed in 48 hours, continued administration of
this type of medication is not recommended. For acute diarrheas and acute exacerbations of functional diarrhea,
treatment beyond 48 hours is usually not necessary.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8583364
Difenoxin decreased the rate of peristalsis in the rat isolated ileum with IC=10.4 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:22 GMT 2025
by
admin
on
Mon Mar 31 17:54:22 GMT 2025
|
| Record UNII |
VQZ63K01IW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C266
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT000047
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
DTXSID30956985
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
100000087945
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
252-640-7
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
59790
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
35607-36-4
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201321
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
C100010
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
VQZ63K01IW
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
C47487
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
VQZ63K01IW
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
37193
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
SUB01691MIG
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | |||
|
235373
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY | RxNorm | ||
|
Difenoxin hydrochloride
Created by
admin on Mon Mar 31 17:54:22 GMT 2025 , Edited by admin on Mon Mar 31 17:54:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |